{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:53:51Z","timestamp":1793944431640,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82000831"],"award-info":[{"award-number":["82000831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipid and glucose metabolism abnormalities are associated with nonalcoholic fatty liver disease (NAFLD). The triglyceride\u2013glucose (TyG) index is a recently developed indicator that can identify individuals at risk for NAFLD. However, the applicability of the TyG index for identifying NAFLD in patients with type 2 diabetes mellitus (T2DM) is unclear. The aim of this study was to investigate the ability of the TyG index to identify individuals at risk for NAFLD in the T2DM population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 2280 participants with T2DM were recruited in this cross-sectional study. The TyG index was calculated, and NAFLD was diagnosed by ultrasonography. Binary logistic regression models were used to evaluate the association of the TyG index, glycemic parameters and lipid parameters with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Logistic regression analysis showed that the TyG index was significantly associated with NAFLD in subjects with T2DM, the odds ratio (OR) were 3.27 (95% confidence interval [CI], 2.03\u20135.27; P\u2009&lt;\u20090.001) for NAFLD in the highest TyG quartile after adjustment for known confounders. In stratified analysis, an elevated TyG index were more remarkably associated with NAFLD in younger patients (&lt;\u200965 years; OR, 2.35; 95% CI, 1.83\u20133.02; P\u2009&lt;\u20090.001), females (OR, 2.69; 95% CI, 1.67\u20134.32; P\u2009&lt;\u20090.001), patients with BMI\u2009&lt;\u200925\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (OR, 2.80; 95% CI, 2.01\u20133.91; P\u2009&lt;\u20090.0001), and with lower high-density lipoprotein cholesterol (&lt;\u20091 mmol\/L; OR, 2.76; 95% CI, 1.98\u20133.83; P\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TyG index is significantly associated with NAFLD and shows superior ability for identify NAFLD risk compared with other lipid and glycemic parameters in T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-022-01172-7","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:03:45Z","timestamp":1666764225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Association between triglyceride\u2013glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus"],"prefix":"10.1186","volume":"22","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851\u201364.","journal-title":"Hepatology"},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705.","journal-title":"Gut"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-018-0692-1","volume":"17","author":"SB Lee","year":"2018","unstructured":"Lee SB, Ahn CW, Lee BK, Kang S, Nam JS, You JH, Kim MJ, Kim MK, Park JS. Association between triglyceride glucose index and arterial stiffness in Korean adults. Cardiovasc Diabetol. 2018;17:41.","journal-title":"Cardiovasc Diabetol"},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12916-020-01824-2","volume":"18","author":"S Hong","year":"2020","unstructured":"Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18:361.","journal-title":"BMC Med"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1080\/10408398.2020.1788501","volume":"61","author":"ADM Brito","year":"2021","unstructured":"Brito ADM, Hermsdorff HHM, Filgueiras MS, Suhett LG, Vieira-Ribeiro SA, Franceschini S, Novaes JF. Predictive capacity of triglyceride-glucose (TyG) index for insulin resistance and cardiometabolic risk in children and adolescents: a systematic review. Crit Rev Food Sci Nutr. 2021;61:2783\u201392.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"1172_CR11","doi-asserted-by":"crossref","unstructured":"Mirr M, Skrypnik D, Bogdanski P, Owecki M. Newly proposed insulin resistance indexes called TyG-NC and TyG-NHtR show efficacy in diagnosing the metabolic syndrome. J Endocrinol Invest 2021.","DOI":"10.1007\/s40618-021-01608-2"},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-019-0982-2","volume":"19","author":"J Alizargar","year":"2020","unstructured":"Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19:8.","journal-title":"Cardiovasc Diabetol"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"204201882095829","DOI":"10.1177\/2042018820958298","volume":"11","author":"V Bullon-Vela","year":"2020","unstructured":"Bullon-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pinto X, Corbella E, Martinez-Gonzalez MA, Sayon-Orea C, Toledo E, et al. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab. 2020;11:2042018820958298.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","volume":"65","author":"M Mota","year":"2016","unstructured":"Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65:1049\u201361.","journal-title":"Metabolism"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12944-020-01393-6","volume":"19","author":"W Guo","year":"2020","unstructured":"Guo W, Lu J, Qin P, Li X, Zhu W, Wu J, Xu N, Zhang Q. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis. 2020;19:218.","journal-title":"Lipids Health Dis"},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"5121574","DOI":"10.1155\/2019\/5121574","volume":"2019","author":"A Kitae","year":"2019","unstructured":"Kitae A, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Can J Gastroenterol Hepatol. 2019;2019:5121574.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW Wong","year":"2018","unstructured":"Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70\u201385.","journal-title":"J Gastroenterol Hepatol"},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHOE Consultation","year":"2004","unstructured":"Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157\u201363.","journal-title":"Lancet"},{"key":"1172_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12944-020-01409-1","volume":"19","author":"Y Li","year":"2020","unstructured":"Li Y, Zheng R, Li J, Feng S, Wang L, Huang Z. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. Lipids Health Dis. 2020;19:229.","journal-title":"Lipids Health Dis"},{"key":"1172_CR21","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/DMSO.S316864","volume":"14","author":"J Liu","year":"2021","unstructured":"Liu J, Guan L, Zhao M, Li Q, Song A, Gao L, Lin H, Zhao J. Association Between the Triglyceride-Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study. Diabetes Metab Syndr Obes. 2021;14:2829\u201339.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1172_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-Jarvinen","year":"2014","unstructured":"Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1172_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018;41:372\u201382.","journal-title":"Diabetes Care"},{"key":"1172_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-020-01077-6","volume":"19","author":"B Zhu","year":"2020","unstructured":"Zhu B, Wang J, Chen K, Yan W, Wang A, Wang W, Gao Z, Tang X, Yan L, Wan Q, et al. A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study. Cardiovasc Diabetol. 2020;19:112.","journal-title":"Cardiovasc Diabetol"},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"14066","DOI":"10.18632\/aging.103358","volume":"12","author":"Y Yu","year":"2020","unstructured":"Yu Y, Xie K, Lou Q, Xia H, Wu D, Dai L, Hu C, Wang K, Shan S, Hu Y, Tang W. The achievement of comprehensive control targets among type 2 diabetes mellitus patients of different ages. Aging. 2020;12:14066\u201379.","journal-title":"Aging"},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12986-018-0313-8","volume":"15","author":"J Luo","year":"2018","unstructured":"Luo J, Chen Q, Shen T, Wang X, Fang W, Wu X, Yuan Z, Chen G, Ling W, Chen Y. Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2018;15:79.","journal-title":"Nutr Metab (Lond)"},{"key":"1172_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70:1457\u201369.","journal-title":"Hepatology"},{"key":"1172_CR28","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"ED Michos","year":"2019","unstructured":"Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2019;381:1557\u201367.","journal-title":"N Engl J Med"},{"key":"1172_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-022-01548-y","volume":"21","author":"J Zhao","year":"2022","unstructured":"Zhao J, Fan H, Wang T, Yu B, Mao S, Wang X, Zhang W, Wang L, Zhang Y, Ren Z, Liang B. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol. 2022;21:123.","journal-title":"Cardiovasc Diabetol"},{"key":"1172_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1172_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/hep.31317","volume":"73","author":"KP Newton","year":"2021","unstructured":"Newton KP, Lavine JE, Wilson L, Behling C, Vos MB, Molleston JP, Rosenthal P, Miloh T, Fishbein MH, Jain AK, et al. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. Hepatology. 2021;73:937\u201351.","journal-title":"Hepatology"},{"key":"1172_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/clpt.2012.108","volume":"92","author":"JR Senior","year":"2012","unstructured":"Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012;92:332\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1172_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/ATVBAHA.112.300075","volume":"33","author":"SA Porter","year":"2013","unstructured":"Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2013;33:139\u201346.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1172_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12986-017-0219-x","volume":"14","author":"L Zhao","year":"2017","unstructured":"Zhao L, Cheng J, Chen Y, Li Q, Han B, Chen Y, Xia F, Chen C, Lin D, Yu X, et al. Serum alanine aminotransferase\/aspartate aminotransferase ratio is one of the best markers of insulin resistance in the Chinese population. Nutr Metab (Lond). 2017;14:64.","journal-title":"Nutr Metab (Lond)"},{"key":"1172_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12944-017-0409-6","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, Yang Y, Yu X. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16:15.","journal-title":"Lipids Health Dis"},{"key":"1172_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-020-01310-x","volume":"19","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, He H, Zeng YP, Yang LD, Jia D, An ZM, Jia WG. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. Lipids Health Dis. 2020;19:134.","journal-title":"Lipids Health Dis"},{"key":"1172_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1161\/CIRCRESAHA.120.317240","volume":"126","author":"KJ Moore","year":"2020","unstructured":"Moore KJ, Shah R. Introduction to the Obesity, Metabolic Syndrome, and CVD Compendium. Circ Res. 2020;126:1475\u20136.","journal-title":"Circ Res"},{"key":"1172_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.metabol.2018.10.011","volume":"92","author":"C Koliaki","year":"2019","unstructured":"Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98\u2013107.","journal-title":"Metabolism"},{"key":"1172_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12986-021-00611-x","volume":"18","author":"J Fan","year":"2021","unstructured":"Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, Yang J, Xia M. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab (Lond). 2021;18:82.","journal-title":"Nutr Metab (Lond)"},{"key":"1172_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T, Jsg N. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586\u201395.","journal-title":"J Gastroenterol"},{"key":"1172_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2213-8587(20)30110-8","volume":"8","author":"N Stefan","year":"2020","unstructured":"Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2020;8:616\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1172_CR42","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","volume":"26","author":"N Stefan","year":"2017","unstructured":"Stefan N, Schick F, Haring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017;26:292\u2013300.","journal-title":"Cell Metab"},{"key":"1172_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12986-021-00551-6","volume":"18","author":"H Dai","year":"2021","unstructured":"Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, Zhao Z, Xu Y, Lu J, Chen Y, et al. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab (Lond). 2021;18:21.","journal-title":"Nutr Metab (Lond)"},{"key":"1172_CR44","doi-asserted-by":"publisher","first-page":"17985","DOI":"10.3748\/wjg.v20.i47.17985","volume":"20","author":"B Zhang","year":"2014","unstructured":"Zhang B, Ding F, Chen T, Xia LH, Qian J, Lv GY. Ultrasound hepatic\/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol. 2014;20:17985\u201392.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01172-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01172-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01172-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T22:03:25Z","timestamp":1667081005000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01172-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01172-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethical Committee of the First Affiliated Hospital of Zhengzhou University, and the requirement for informed consent was waived. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}